Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 2/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | BCL6 | P41182 | 4/20 | 0.46 |
| ▸ | BCOR | Q6W2J9 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.45 |
| ▸ | KLK7 | P49862 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10338441 | 0.76 | PDE3B (0.60) | PDE3BPDE3AKDM4EALDH1A1MAPT | |
| SCHEMBL21927159 | 0.74 | AURKA (0.47) | PDE3BPDE3AGAAKDM4EBCL6 | |
| SCHEMBL10338403 | 0.74 | PDE3B (0.61) | PDE3BPDE3AKDM4EALDH1A1RAD52 | |
| SCHEMBL31192609 | 0.73 | PDE3B (1.00) | PDE3BPDE3A | |
| SCHEMBL15501260 | 0.72 | AURKA (0.51) | GAAKDM4EBCL6BCORALDH1A1 | |
| SCHEMBL21925305 | 0.72 | AURKA (0.48) | GAAKDM4EBCL6BCORALDH1A1 | |
| SCHEMBL12106712 | 0.72 | KDM4E (0.62) | GAAKDM4EALDH1A1MAPTKLK7 | |
| SCHEMBL22201605 | 0.72 | HPGD (0.64) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL26418197 | 0.70 | MAPT (0.50) | GAAKDM4EBCL6BCORALDH1A1 | |
| SCHEMBL20772662 | 0.70 | MAPT (0.69) | GAAKDM4EALDH1A1MAPTKLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2059572-A | — | — | None | — | — | JP | disclosed |
| US-20210147382-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-05-20 | — | — | US | disclosed |
| JP-H0259572-A | BENZIMIDAZOLONE DERIVATIVE OR SALTS THEREOF | MITSUBISHI KASEI CORP | 1990-02-28 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147382-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | BCL6, BCL6B, BCL3 | PDE3B 2390/4885PDE3A 3089/4885GAA 2771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.